In fact, mepolizumab and benralizumab, which are humanized monoclonal antibodies targeting IL-5 and IL-5Rα, respectively, have both shown remarkable therapeutic effects in various types of eosinophilic diseases, including ECRS and asthma (58). The gene discussed is IL5; the disease is asthma.